Lyndsey E Collins-Praino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4493101/publications.pdf

Version: 2024-02-01

279798 345221 53 1,462 23 36 citations g-index h-index papers 57 57 57 1757 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Impact of "chemobrain―in childhood cancer survivors on social, academic, and daily living skills: a qualitative systematic review protocol. JBI Evidence Synthesis, 2022, 20, 222-228.	1.3	1
2	Development and Co-design of NeuroOrb: A Novel "Serious Gaming―System Targeting Cognitive Impairment in Parkinson's Disease. Frontiers in Aging Neuroscience, 2022, 14, 728212.	3.4	1
3	Characterizing the Dynamic Disassembly/Reassembly Mechanisms of Encapsulin Protein Nanocages. ACS Omega, 2022, 7, 823-836.	3.5	11
4	Traumatic axonal injury as a key driver of the relationship between traumatic brain injury, cognitive dysfunction, and dementia., 2022,, 475-486.		0
5	Injury during adolescence leads to sex-specific executive function deficits in adulthood in a pre-clinical model of mild traumatic brain injury. Behavioural Brain Research, 2021, 402, 113067.	2.2	7
6	More than motor impairment: A spatiotemporal analysis of cognitive impairment and associated neuropathological changes following cortical photothrombotic stroke. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2439-2455.	4.3	21
7	Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks. Neurotoxicity Research, 2021, 39, 897-923.	2.7	21
8	Effects of Remote Immune Activation on Performance in the 5-Choice Serial Reaction Time Task Following Mild Traumatic Brain Injury in Adolescence. Frontiers in Behavioral Neuroscience, 2021, 15, 659679.	2.0	2
9	Loss of park7 activity has differential effects on expression of iron responsive element (IRE) gene sets in the brain transcriptome in a zebrafish model of Parkinson's disease. Molecular Brain, 2021, 14, 83.	2.6	7
10	The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. Brain, Behavior, & Immunity - Health, 2021, 14, 100242.	2.5	14
11	Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?. Molecular Neurobiology, 2021, 58, 5986-6005.	4.0	20
12	Optimizing Cognitive Training for the Treatment of Cognitive Dysfunction in Parkinson's Disease: Current Limitations and Future Directions. Frontiers in Aging Neuroscience, 2021, 13, 709484.	3.4	7
13	Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?. International Journal of Molecular Sciences, 2021, 22, 13101.	4.1	51
14	Are the protective benefits of vitamin D in neurodegenerative disease dependent on route of administration? A systematic review. Nutritional Neuroscience, 2020, 23, 251-280.	3.1	15
15	The need to incorporate aged animals into the preclinical modeling of neurological conditions. Neuroscience and Biobehavioral Reviews, 2020, 109, 114-128.	6.1	33
16	Evaluating spatiotemporal microstructural alterations following diffuse traumatic brain injury. Neurolmage: Clinical, 2020, 25, 102136.	2.7	24
17	Cerebrovascular function during cognition in Parkinson's disease: A functional transcranial Doppler sonography study. Journal of the Neurological Sciences, 2020, 408, 116578.	0.6	9
18	The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making. Pharmacology Biochemistry and Behavior, 2020, 198, 173035.	2.9	8

#	Article	IF	CITATIONS
19	Maladaptive avoidance patterns in Parkinson's disease are exacerbated by symptoms of depression. Behavioural Brain Research, 2020, 382, 112473.	2.2	2
20	Infants who die in shared sleeping situations differ from those who die while sleeping alone. Acta Paediatrica, International Journal of Paediatrics, 2019, 108, 611-614.	1.5	13
21	Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism and Related Disorders, 2019, 65, 20-31.	2.2	78
22	Age, but not severity of injury, mediates decline in executive function: Validation of the rodent touchscreen paradigm for preclinical models of traumatic brain injury. Behavioural Brain Research, 2019, 368, 111912.	2.2	7
23	Cognitive and neuropsychiatric impairments vary as a function of injury severity at 12 months post-experimental diffuse traumatic brain injury: Implications for dementia development. Behavioural Brain Research, 2019, 365, 66-76.	2.2	15
24	Evaluation of early chronic functional outcomes and their relationship to pre-frontal cortex and hippocampal pathology following moderate-severe traumatic brain injury. Behavioural Brain Research, 2018, 348, 127-138.	2.2	20
25	Medullary Astrogliosis in Sudden Infant Death Syndrome Varies With Sleeping Environment: Evidence for Different Mechanisms of Death in Alone Versus Co-sleepers?. Journal of Child Neurology, 2018, 33, 269-274.	1.4	9
26	The effect of an acute systemic inflammatory insult on the chronic effects of a single mild traumatic brain injury. Behavioural Brain Research, 2018, 336, 22-31.	2.2	37
27	Can neuroimmune mechanisms explain the link between ultraviolet light (UV) exposure and addictive behavior? Brain, Behavior, and Immunity, 2018, 73, 125-132.	4.1	3
28	Cerebrovascular contribution to dementia development after traumatic brain injury: promises and problems. Annals of Translational Medicine, 2018, 6, S58-S58.	1.7	1
29	Toll like receptor 4 activation can be either detrimental or beneficial following mild repetitive traumatic brain injury depending on timing of activation. Brain, Behavior, and Immunity, 2017, 64, 124-139.	4.1	33
30	Evolution and significance of the triple risk model in sudden infant death syndrome. Journal of Paediatrics and Child Health, 2017, 53, 112-115.	0.8	25
31	Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury?. Brain, Behavior, and Immunity, 2017, 60, 369-382.	4.1	66
32	Pumping the Brakes: Neurotrophic Factors for the Prevention of Cognitive Impairment and Dementia after Traumatic Brain Injury. Journal of Neurotrauma, 2017, 34, 971-986.	3.4	15
33	Physiological and Behavioral Assessment of Tremor in Rodents. , 2015, , 631-640.		1
34	<i>APOE</i> $\hat{l}\mu$ 4 and risk for Alzheimer's disease: Do regionally distributed white matter hyperintensities play a role?. Alzheimer's and Dementia, 2014, 10, 619-629.	0.8	59
35	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	5.2	39
36	Deep brain stimulation of the subthalamic nucleus reverses oral tremor in pharmacological models of parkinsonism: interaction with the effects of adenosine A _{2A} antagonism. European Journal of Neuroscience, 2013, 38, 2183-2191.	2.6	18

#	Article	IF	CITATIONS
37	Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor. Pharmacology Biochemistry and Behavior, 2013, 105, 105-111.	2.9	31
38	Conditional neural knockout of the adenosine A2A receptor and pharmacological A2A antagonism reduce pilocarpine-induced tremulous jaw movements: Studies with a mouse model of parkinsonian tremor. European Neuropsychopharmacology, 2013, 23, 972-977.	0.7	25
39	The novel adenosine A2A antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacology Biochemistry and Behavior, 2012, 102, 477-487.	2.9	44
40	Extracellular GABA in globus pallidus increases during the induction of oral tremor by haloperidol but not by muscarinic receptor stimulation. Behavioural Brain Research, 2012, 234, 129-135.	2.2	14
41	The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacology Biochemistry and Behavior, 2012, 100, 498-505.	2.9	36
42	Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor. Frontiers in Systems Neuroscience, 2011, 5, 49.	2.5	33
43	Oral tremor induced by galantamine in rats: A model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease. Pharmacology Biochemistry and Behavior, 2011, 99, 414-422.	2.9	31
44	Role of dopamine–adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation. Future Neurology, 2010, 5, 377-392.	0.5	33
45	Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX. Pharmacology Biochemistry and Behavior, 2010, 94, 561-569.	2.9	41
46	The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacology Biochemistry and Behavior, 2010, 95, 479-484.	2.9	45
47	Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity. Behavioural Brain Research, 2010, 211, 148-155.	2.2	45
48	Nucleus accumbens and effort-related functions: behavioral and neural markers of the interactions between adenosine A2A and dopamine D2 receptors. Neuroscience, 2010, 166, 1056-1067.	2.3	103
49	Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. European Neuropsychopharmacology, 2010, 20, 112-122.	0.7	69
50	The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology, 2009, 204, 103-112.	3.1	105
51	Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. Psychopharmacology, 2009, 206, 223-232.	3.1	21
52	Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. Behavioural Brain Research, 2009, 201, 216-222.	2.2	88
53	Telencephalic ablation results in decreased startle response in goldfish. Brain Research, 2006, 1111, 162-165.	2.2	4